Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer

Background: Immunotherapy has been approved for the treatment of metastatic colorectal cancer. The efficacy and safety of neoadjuvant immunotherapy for the treatment of non-metastatic colorectal cancer remains unclear. We tried to explore clinical effect of neoadjuvant immunotherapy in the treatment of non-metastatic colorectal cancer.Methods: We searched the databases (PubMed, Wanfang Embase, Cochrane Library and China National Knowledge Infrastructure databases) to obtain suitable articles up to September 2022. The primary outcomes of pathological complete response (pCRs), major pathological response (MPR), objective response rate (ORR), R0-resection and anus preserving rate were collected and evaluated. Secordary outcomes (pCRs and MPR) of subgroup analysis between deficient mismatch repair/microsatellite instability-high group (dMMR/MSI-H) and proficient mismatch repair/microsatellite stable group (pMMR/MSS) and outcomes for rectal cancer were analyzed for the final results.Results: We included ten articles and 410 cases of non-metastatic colorectal cancer with neoadjuvant immunotherapy. There were 113 (27.5%) cases with the dMMR/MSI-H status and 167 (40.7%) cases with the pMMR/MSS status. pCRs was found in 167/373 (44.6%) patients (ES: 0.49, 95% CI: 0.36 to 0.62, P < 0.01, chi(2) = 65.3, P < 0.01, I (2) = 86.2%) and MPR was found in 194/304 (63.8%) patients (ES: 0.66, 95% CI: 0.54 to 0.78, P < 0.01, chi(2) = 42.55, P < 0.01, I (2) = 81.2%) with the random-effects model and huge heterogeneity. In the subgroup analysis, pCRs was higher in the dMMR/MSI-H group than the pMMR/MSS group in the fixed-effects model with minimal heterogeneity (OR: 3.55, 95% CI: 1.74 to 7.27, P < 0.01, chi(2) = 1.86, P=0.6, I (2) = 0%). pCRs was found in 58/172 (33.9%) rectal cancer patients (ES: 0.33, 95% CI: 0.26 to 0.40, P < 0.01, chi(2) = 3.04, P=0.55, I (2) = 0%) with the fixed-effects model and little heterogeneity.Conclusion: Neoadjuvant immunotherapy could increase pCRs and MPR rate for non-metastatic colorectal cancer. Neoadjuvant immunotherapy could achieve better pCRs rate in dMMR/MSI-H group than in the pMMR/MSS group. Neoadjuvant immunotherapy could be another treatment option for non-metastatic colorectal cancer.Systematic review registration:https://www.crd.york.ac.uk/prospero/#myprospero, identifier CRD42022350523.

Automated summary

This study aimed to explore the clinical effect of neoadjuvant immunotherapy in non-metastatic colorectal cancer. Through the analysis of ten articles and 410 cases, it was found that neoadjuvant immunotherapy could increase the rates of pathological complete response and major pathological response. Subgroup analysis showed that the rate of pathological complete response was higher in the deficient mismatch repair/microsatellite instability-high group (dMMR/MSI-H) compared to the proficient mismatch repair/microsatellite stable group (pMMR/MSS). In conclusion, neoadjuvant immunotherapy could be another treatment option for non-metastatic colorectal cancer.